SynthesisWorld journal of urology2023
Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Synthesis in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review.Investigative and clinical urology · 2025Pooled it
- Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.BJU international · 2026Article
- Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.Biosensors · 2026Article
- Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.Cancer cytopathology · 2026Article
- Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review.International urology and nephrology · 2026Article
- Machine learning prediction of postoperative recurrence in bladder cancer using clinical and laboratory indicators.Scientific reports · 2026Article
- Review
- Perioperative cognitive dysfunction in bladder cancer patients, causal factors, and possible interventions.Frontiers in medicine · 2026Review
- Postoperative continuous saline bladder irrigation reduces active urinary cancer cells: a prospective study in NMIBC.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Article
- Review
- Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis:Current medicinal chemistry · 2025Article
- Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial.European urology open science · 2025Article
- Advances in the immunological microenvironment and immunotherapy of bladder cancer.Frontiers in immunology · 2025Review
- Evaluation of expression profiles of APOA4, CEACAM1, CD147, DJ-1/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinomas using immunohistochemical assays.Frontiers in oncology · 2025Article
- Article
- Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.Biology direct · 2024Article
- Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer.Antioxidants (Basel, Switzerland) · 2024Review
- Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.Proteomes · 2023Review
- 3D Printing for Cancer Diagnosis: What Unique Advantages Are Gained?ACS materials Au · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer detection and follow-up is based on cystoscopy and/or cytology, but it remains imperfect and invasive. Current research focuses on diagnostic biomarkers that could improve bladder cancer detection and follow-up by discriminating patients at risk of aggressive cancer who need confirmatory TURBT (Transurethral Resection of Bladder Tumour) from patients at no risk of aggressive cancer who could be spared from useless explorations.
objectiveTo perform a systematic review of data on the clinical validity and clinical utility of eleven urinary biomarkers (VisioCyt
methodsAll available studies on the 11 biomarkers published between May 2010 and March 2021 and present in MEDLINE
resultsMost studies on urinary biomarkers had a prospective design and high level of evidence. However, their results should be interpreted with caution given the heterogeneity among studies. Most of the biomarkers under study displayed higher detection sensitivity compared with cytology, but lower specificity. Some biomarkers may have clinical utility for NMIBC surveillance in patients with negative or equivocal cystoscopy or negative or atypical urinary cytology findings, and also for recurrence prediction.
conclusionUrinary biomarkers might have a complementary place in bladder cancer diagnosis and NMIBC surveillance. However, their clinical benefit remains to be confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.